Control fever due to acute mastitis with new FDA approval

BANAMINE^® TRANSDERMAL was determined to be safe and effective in controlling fever due to acute mastitis.

TRIAL SETUP

Multisite field study with lactating dairy cows between 2 and 12 years of age.
Cows were not restricted from licking, and in most cases, were free to contact and interact with at least one other cow.
Cows were also protected from rain and misting systems and did not have access to a cow brush.
Six hours after treatment rectal temperatures were measured.
Considered a treatment success if rectal temperature was reduced by ≥ 2º F.

RESULTS

Treatment success was 95% for animals receiving BANAMINE TRANSDERMAL (p<0.0001) compared to 35% of untreated controls.
There were no treatment-related adverse reactions within six days following dosing.

1. Evaluation of the efficacy and safety of flunixin transdermal solution for the control of pyrexia and/or inflammation associated with naturally occurring bovine mastitis (Study No. S12074-00). 2014.

IMPORTANT SAFETY INFORMATION:

Banamine TD: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. Milk that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of the last treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in milk and/or calves born to these cows or heifers. Not for use in beef and dairy bulls intended for breeding over 1 year of age, beef calves less than 2 months of age, dairy calves, and veal calves. Do not use within 48 hours of expected parturition. Approved only as a single topical dose in cattle. For complete information on BANAMINE^® TRANSDERMAL, see accompanying product package insert.